The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Clinical characteristics of h-MDS
Enrico Attardi, MD, University of Rome Tor Vergata, Rome, Italy, discusses hypocellular myelodysplastic syndromes (h-MDS), a rare subgroup of MDS affecting 10-15% of patients with MDS, describing the results of a study which evaluated the clinical features, overall survival (OS), and treatment of h-MDS in comparison to patients with normal MDS. The study revealed that the immunological landscape of patients with h-MDS is characterized by T and NK cell expansion, which is more common in patients with high-risk (HR) h-MDS and low-risk (LR) h-MDS respectively. These findings could help personalize treatments in this patient population. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
